Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor
23 drugs across 15 manufacturers|22 Generic,1 Brand
The Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor class contains 23 NDCs from 15 manufacturers (22 generic, 1 brand), at an average NADAC of $5.38 per unit. Every drug, manufacturer, and price in this FDA-defined pharmacologic class is listed below.
Total Drugs
23
22G / 1B
Manufacturers
15
Avg $5.3779/unit
Avg 7d Change
-1.12%
Across 22 drugs with changes
7d Activity
of 23 total drugs
Class Price Trend
Monthly average NADAC price per unit, split by generic and brand
Manufacturer Breakdown
15 manufacturers producing drugs in this therapeutic class(1 pricing outlier)
and 3 more manufacturers
Follow this class across the site
These links connect the therapeutic class page to the specific suppliers, markets, and trend surfaces that help users keep exploring.
Top supplier
Major Pharmaceuticals manufacturer profile
Review the supplier with the strongest product footprint inside this therapeutic class.
Lead market
Valganciclovir market page
Move from the therapeutic class into the molecule that appears most often in this class-specific portfolio.
Trend hub
Latest trend hub
Compare this class against the rest of the weekly NADAC trend surface.
Guide
Understanding NADAC pricing
Use the explainer when you need a plain-English refresher on how these class-level numbers are published and interpreted.
Frequently Asked Questions
How many drugs are in the Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor class?
The Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor class contains 23 NDCs from 15 manufacturers — 22 generic and 1 brand product.
What is the average price of Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor drugs?
The average NADAC for the Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor class is $5.3779 per unit across 23 NDCs.
Which manufacturers make Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor drugs?
15 manufacturers make drugs in the Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor class. Ranked by number of NDCs, the largest are Major Pharmaceuticals (3), American Health Packaging (3), Ajanta Pharma USA Inc. (2), Camber Pharmaceuticals Inc. (2), Strides Pharma Inc. (2).
How has Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor pricing changed recently?
Over the past 7 days, 10 NDCs in this class rose and 12 fell, with a class-wide average change of -1.1%.